HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure.

AbstractOBJECTIVES:
This study sought to identify the role of annexin A1 (AnxA1) as a congestion marker in acute heart failure (AHF) and to identify its putative role in predicting clinical outcomes.
BACKGROUND:
AnxA1 is a protein that inhibits inflammation following ischemia-reperfusion injury in cardiorenal tissues. Because AHF is a state of tissue hypoperfusion, we hypothesized that plasma AnxA1 levels are altered in AHF.
METHODS:
In the Renal Optimization Strategies Evaluation (ROSE) trial, patients hospitalized for AHF with kidney injury were randomized to receive dopamine, nesiritide, or placebo for 72 hours in addition to diuresis. In a subanalysis, plasma AnxA1 levels were measured at baseline and at 72 hours in 275 patients. Participants were divided into 3 tertiles based on their baseline AnxA1 levels.
RESULTS:
The prevalence of peripheral edema 2+ increased with increasing AnxA1 levels (P < .007). Cystatin C, blood urea nitrogen, and kidney injury molecule-1 plasma levels were higher among participants in tertile 3 vs tertiles 1 or 2 (P< .05). Patients with a congestion score of 4 had a mean baseline AnxA1 level 8.63 units higher than those with a congestion score of 0 (P = .03). Patients in tertiles 2 and 3 were twice as likely to experience creatinine elevation as patients in tertile 1 (P = .03). Patients in tertiles 2 and 3 were at a higher risk of 60-day all-cause mortality or heart failure hospitalization and 180-day all-cause mortality (P < .05).
CONCLUSIONS:
Among patients hospitalized for AHF with impaired kidney function, elevated AnxA1 levels are associated with worse congestion, higher risk for further creatinine elevation, and higher rates of 60-day morbidity or all-cause mortality and 180-day all-cause mortality.
CLINICAL TRIAL REGISTRATION:
clinicaltrials.gov Identifier: NCT01132846.
AuthorsFadi W Adel, Aruna Rikhi, Siu-Hin Wan, Seethalakshmi R Iyer, Hrishikesh Chakraborty, Steven McNulty, W H Wilson Tang, G Michael Felker, Michael M Givertz, Horng H Chen
JournalJournal of cardiac failure (J Card Fail) Vol. 26 Issue 8 Pg. 727-732 (Aug 2020) ISSN: 1532-8414 [Electronic] United States
PMID32473378 (Publication Type: Journal Article, Randomized Controlled Trial)
CopyrightCopyright © 2020 Elsevier Inc. All rights reserved.
Chemical References
  • Annexin A1
  • Biomarkers
  • Natriuretic Peptide, Brain
Topics
  • Acute Disease
  • Annexin A1
  • Biomarkers
  • Heart Failure (diagnosis, drug therapy, epidemiology)
  • Humans
  • Natriuretic Peptide, Brain
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: